Congressional Hearing on AbbVie Drug Pricing
January 1, 2021
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
The Frame
This hearing represents a formal congressional inquiry into the pricing strategies of major pharmaceutical companies, which directly impacts the cost of prescription medications for patients and the federal budget.
Potentially affected actors named in the source documents. Mention is not a position.
AbbVie Inc.
The company is the subject of a congressional investigation regarding its drug pricing practices.
Patients
Patients who rely on prescription medications are affected by the pricing strategies discussed in the hearing.
Last recorded activity January 1, 2021.
Next step not available in the current record.
Summary
Key Facts
- The hearing was held on May 18, 2021, by the House Committee on Oversight and Reform.
- The committee released a sixth staff report specifically regarding AbbVie's pricing of Humira and Imbruvica.
- The investigation into pharmaceutical pricing has been ongoing for over two years.
- Witnesses included Dr. Aaron Kesselheim, Mr. Craig Garthwaite, Mr. Tahir Amin, and AbbVie CEO Richard Gonzalez.
- The committee entered multiple reports and statements into the record, including documents from I-MAK, Families USA, and the American Economic Liberties Project.
- The hearing is part of a series titled 'Unsustainable Drug Prices'.
Why It Matters
This hearing represents a formal congressional inquiry into the pricing strategies of major pharmaceutical companies, which directly impacts the cost of prescription medications for patients and the federal budget.
Frequently Asked Questions
What was the purpose of this hearing?
Which drugs were specifically discussed?
News Coverage
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Long-term Congressional Oversight
The document highlights a multi-year, sustained effort by the House Oversight Committee to investigate pharmaceutical pricing across multiple sessions of Congress.
Connected Entities
Sources
www.govinfo.gov
Analysis Score
0–100- Significance85How much this matters to a regular citizen
- Controversy75Intensity of disagreement among stakeholders
- Entertainment40Compellingness for a non-policy-wonk reader
- Buzz30Current news / social attention level
Publisher tools